Evidence map›Paper›PMID 33290418›Full record

ArticlePLoS pathogens2020

A small molecule that mitigates bacterial infection disrupts Gram-negative cell membranes and is inhibited by cholesterol and neutral lipids.

Jamie L Dombach, Joaquin L J Quintana, Toni A Nagy, Chun Wan, Amy L Crooks, Haijia Yu, Chih-Chia Su, Edward W Yu, Jingshi Shen, Corrella S Detweiler

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jamie L DombachDepartment of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, Colorado, United States of America.
Joaquin L J QuintanaDepartment of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, Colorado, United States of America.
Toni A NagyDepartment of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, Colorado, United States of America.
Chun WanDepartment of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, Colorado, United States of America.ORCID 0000-0002-8827-0552
Amy L CrooksDepartment of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, Colorado, United States of America.ORCID 0000-0001-6629-2753
Haijia YuDepartment of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, Colorado, United States of America.
Chih-Chia SuDepartment of Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States of America.ORCID 0000-0003-3646-327X
Edward W YuDepartment of Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States of America.ORCID 0000-0001-5912-1227
Jingshi ShenDepartment of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, Colorado, United States of America.
Corrella S DetweilerDepartment of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, Colorado, United States of America.ORCID 0000-0002-7783-0876
University of Colorado Boulder · USCase Western Reserve University · US

Funding

Emerging antibiotic resistance in Gram-negative pathogensR01AI145069 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI YU, EDWARD W · 2019 to 2023
$3.3M
Protein-membrane interactions in regulated exocytosisR35GM126960 · NIGMS · UNIVERSITY OF COLORADO · PI Jingshi Shen · 2018 to 2026
$3.2M
A Novel Screen for Antibacterials that Are Non-Toxic to MammalsR33AI121365 · NIAID · UNIVERSITY OF COLORADO · PI DETWEILER, CORRELLA S, WANG, XIANG · 2018 to 2020
$1.4M
Mechanisms of GLUT4 ExocytosisR01DK124431 · NIDDK · UNIVERSITY OF COLORADO · PI SHEN, JINGSHI · 2020 to 2022
$1.1M
A Small Molecule That Blocks Salmonella Replication in MacrophagesR21AI151979 · NIAID · UNIVERSITY OF COLORADO · PI DETWEILER, CORRELLA S · 2021 to 2022
$424k
Chemical Probes for Bacteria-Macrophage InteractionsR21AI126453 · NIAID · UNIVERSITY OF COLORADO · PI DETWEILER, CORRELLA S · 2016 to 2017
$423k
A Novel Screen for Antibacterials that Are Non-Toxic to MammalsR21AI121365 · NIAID · UNIVERSITY OF COLORADO · PI DETWEILER, CORRELLA S, WANG, XIANG · 2016 to 2017
$412k
NIAID NIH HHS R01 AI145069NIAID NIH HHS R21 AI121365NIAID NIH HHS R21 AI126453NIAID NIH HHS R21 AI151979NIAID NIH HHS R33 AI121365NIDDK NIH HHS R01 DK124431NIGMS NIH HHS R35 GM126960
6 · The paper itself

Abstract

Infections caused by Gram-negative bacteria are difficult to fight because these pathogens exclude or expel many clinical antibiotics and host defense molecules. However, mammals have evolved a substantial immune arsenal that weakens pathogen defenses, suggesting the feasibility of developing therapies that work in concert with innate immunity to kill Gram-negative bacteria. Using chemical genetics, we recently identified a small molecule, JD1, that kills Salmonella enterica serovar Typhimurium (S. Typhimurium) residing within macrophages. JD1 is not antibacterial in standard microbiological media, but rapidly inhibits growth and curtails bacterial survival under broth conditions that compromise the outer membrane or reduce efflux pump activity. Using a combination of cellular indicators and super resolution microscopy, we found that JD1 damaged bacterial cytoplasmic membranes by increasing fluidity, disrupting barrier function, and causing the formation of membrane distortions. We quantified macrophage cell membrane integrity and mitochondrial membrane potential and found that disruption of eukaryotic cell membranes required approximately 30-fold more JD1 than was needed to kill bacteria in macrophages. Moreover, JD1 preferentially damaged liposomes with compositions similar to E. coli inner membranes versus mammalian cell membranes. Cholesterol, a component of mammalian cell membranes, was protective in the presence of neutral lipids. In mice, intraperitoneal administration of JD1 reduced tissue colonization by S. Typhimurium. These observations indicate that during infection, JD1 gains access to and disrupts the cytoplasmic membrane of Gram-negative bacteria, and that neutral lipids and cholesterol protect mammalian membranes from JD1-mediated damage. Thus, it may be possible to develop therapeutics that exploit host innate immunity to gain access to Gram-negative bacteria and then preferentially damage the bacterial cell membrane over host membranes.

Indexed as

Gram-Negative Bacterial InfectionsImmunity, InnateAnimalsAnti-Bacterial AgentsCell MembraneGram-Negative BacteriaMacrophagesMembrane LipidsMiceMice, Inbred C57BLAnti-Bacterial AgentsMembrane Lipids

Identifiers

PMID33290418
PMCPMC7748285
OpenAlexW3110696757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.